iNtRON Biotechnology, Inc.
048530.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$86.19B
Close$
$-258.76
109.7% downside
Current Fair Value
109.7% downsideOvervalued by 109.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $86.19 Billion |
|---|---|
| Enterprise Value | $64.95 Billion |
| Annual dividend | $100.00 |
| Dividend yield | 3.58% |
| Earnings per Share | $-271.16 |
| Beta | 0.05 |
| Outstanding Shares | 31,208,501 |
Return
| Return on Equity | -17.11% |
|---|---|
| Return on Assets | -15.56% |
| Return on Invested Capital | -16.37% |
Valuation & Multiples
| P/E Ratio | -8.5 |
|---|---|
| PEG | -8.24 |
| Price to Sales | 11.44 |
| Price to Book Ratio | 1.33 |
| Enterprise Value to Revenue | 8.96 |
| Enterprise Value to EBIT | -6.17 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.08 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
$16.56
Consensus analyst estimateRevenue Estimate
$7.32 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$16.56
Consensus analyst estimateRevenue Estimate
$7.32 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About iNtRON Biotechnology, Inc.
76 employees
CEO: Seong-Jun Yoon
iNtRON Biotechnology, Inc. is a global developer of biopharmaceutical solutions focused on averting and remedying human ailments. Its development efforts encompass a range of bacteriophage and endoricin-based therapeutics. This company, ...